KCT0000355
Recruiting
未知
Prevention of Cardiovascular events in ischemic stroke patients with high risk of cerebral hemorrhage: PICASSO study
ConditionsDiseases of the nervous system
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Diseases of the nervous system
- Sponsor
- Asan Medical Center
- Enrollment
- 1600
- Status
- Recruiting
- Last Updated
- 7 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •patinets having high\-risk of cerebral hemorrage proved by past history of cerebral hemorrhage or multiple microbleeds on MRI among acute stroke patients who were admitted in 4 hostpitals
Exclusion Criteria
- •acute stroke patients with cardioembolic source or
- •patients within 6 months of life expectancy
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Improving the prevention of vascular events after stroke or transient ischemic attackISRCTN63816609Royal Devon and Exeter Foundation Trust (UK)30
Active, not recruiting
Phase 1
Can the heart drug enalapril prevent heart damage in patients with newly diagnosed breast cancer and lymphoma receiving chemotherapy?Prevention of cardiotoxicityMedDRA version: 20.0Level: PTClassification code 10048610Term: CardiotoxicitySystem Organ Class: 10007541 - Cardiac disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2017-001094-16-GBSouth Tees NHS Foundation Trust170
Completed
Not Applicable
Secondary Prevention of Adverse Cardiovascular Events in Cases with Anomalous Origins of Coronary Arteries: Clinical Features, Management, and Long-Term OutcomeAnomalous Origin of the Coronary ArteryJPRN-UMIN000030629ihon University60
Active, not recruiting
Not Applicable
Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a history oF ischaemic strOke or tRansient ischaeMic attack.The PERFORM Study.An international, randomised, double-blind, two parallel group study comparing terutroban 30 mg o.d. versus aspirin 100 mg o.d. administered orally for a 3-year mean duration (event driven trial). - PERFORMIschaemic stroke or transient ischaemic attackMedDRA version: 7.0Level: PTClassification code 10008190EUCTR2005-003700-10-BEInstitut de Recherches Internationales Servier18,000
Active, not recruiting
Not Applicable
Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a history oF ischaemic strOke or tRansient ischaeMic attack.The PERFORM Study.An international, randomised, double-blind, two parallel group study comparing terutroban 30 mg o.d. versus aspirin 100 mg o.d. administered orally for a 3-year mean duration (event driven trial). - PERFORMEUCTR2005-003700-10-LTInstitut de Recherches Internationales Servier18,000